Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning
Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid carcinoma is highly variable. We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[18F]fluoro-2-deoxygluc...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2006-02, Vol.91 (2), p.498-505 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 505 |
|---|---|
| container_issue | 2 |
| container_start_page | 498 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 91 |
| creator | Robbins, Richard J. Wan, Qiang Grewal, Ravinder K. Reibke, Roland Gonen, Mithat Strauss, H. William Tuttle, R. Michael Drucker, William Larson, Steven M. |
| description | Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid carcinoma is highly variable. We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[18F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis.
Design/Patients: The initial FDG-positron emission tomography (PET) scans from 400 thyroid cancer patients were retrospectively reviewed and compared with overall survival (median follow-up, 7.9 yr). We examined the prognostic value of clinical information such as gender, age, serum thyroglobulin, American Joint Committee on Cancer (AJCC) stage, histology, radioiodine avidity, FDG-PET positivity, number of FDG-avid lesions, and the glycolytic rate of the most active lesion.
Results: Age, initial stage, histology, thyroglobulin, radioiodine uptake, and PET outcomes all correlated with survival by univariate analysis. However, only age and PET results continued to be strong predictors of survival under multivariate analysis. The initial American Joint Committee on Cancer stage was not a significant predictor of survival by multivariate analysis. There were significant inverse relationships between survival and both the glycolytic rate of the most active lesion and the number of FDG-avid lesions.
Conclusions: FDG-PET scanning is a simple, expensive, but powerful means to restage thyroid cancer patients who develop subsequent metastases, assigning them to groups that are either at low (FDG negative) or high (FDG positive) risk of cancer-associated mortality. We propose that the aggressiveness of therapy for metastases should match the FDG-PET status. |
| doi_str_mv | 10.1210/jc.2005-1534 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67632256</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/jc.2005-1534</oup_id><sourcerecordid>67632256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5724-d154f9f207971d1a34e1714c6d226e5c5276ff5541a8b410ffc3fad17b4e8a3c3</originalsourceid><addsrcrecordid>eNp1kd2LEzEUxQdR3Lr65rMMiPpi1tx8zjxq3a7CiotWEERCmsm0qTPJmMyw9tl_3JQWCqKBJPfhd0_OzSmKx4AvgAB-tTUXBGOOgFN2p5hBzTiSUMu7xQxjAqiW5OtZ8SClLcbAGKf3izMQFNOKilnx-5PVHVq63pY3Max9SC6VbYjlBzvqNOrRmXK52cXgmnKuo3E-9Lp8o5NtyuBLgr5Btfi-6KYQAyLorQ2_dqhBV91kQrLoJuuNMYOXvUvJ5WIZ-rCOetjsys9Ge-_8-mFxr9Vdso-O93nxZXG5nL9D1x-v3s9fXyPDJWGoAc7auiVY1hIa0JRZkMCMaAgRlhtOpGhbzhnoasUAt62hrW5ArpitNDX0vHh-0B1i-DnZNKpsytiu096GKSkhBSWEiww-_Qvchin67E1REIwBUMEz9fJAmRhSirZVQ3S9jjsFWO2jUVuj9tGofTQZf3IUnVa9bU7wMYsMPDsCOhndtVF749KJk6yqa7kXYgfuNnSjjelHN93aqDY5yHGjcF5MyArllwXOB0Z5k33bi0NbmIb_OUVHp_RAWt8EE523Q7QpnT7hn_P9AQTYwlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3164411365</pqid></control><display><type>article</type><title>Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning</title><source>Oxford University Press Journals</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Robbins, Richard J. ; Wan, Qiang ; Grewal, Ravinder K. ; Reibke, Roland ; Gonen, Mithat ; Strauss, H. William ; Tuttle, R. Michael ; Drucker, William ; Larson, Steven M.</creator><creatorcontrib>Robbins, Richard J. ; Wan, Qiang ; Grewal, Ravinder K. ; Reibke, Roland ; Gonen, Mithat ; Strauss, H. William ; Tuttle, R. Michael ; Drucker, William ; Larson, Steven M.</creatorcontrib><description>Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid carcinoma is highly variable. We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[18F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis.
Design/Patients: The initial FDG-positron emission tomography (PET) scans from 400 thyroid cancer patients were retrospectively reviewed and compared with overall survival (median follow-up, 7.9 yr). We examined the prognostic value of clinical information such as gender, age, serum thyroglobulin, American Joint Committee on Cancer (AJCC) stage, histology, radioiodine avidity, FDG-PET positivity, number of FDG-avid lesions, and the glycolytic rate of the most active lesion.
Results: Age, initial stage, histology, thyroglobulin, radioiodine uptake, and PET outcomes all correlated with survival by univariate analysis. However, only age and PET results continued to be strong predictors of survival under multivariate analysis. The initial American Joint Committee on Cancer stage was not a significant predictor of survival by multivariate analysis. There were significant inverse relationships between survival and both the glycolytic rate of the most active lesion and the number of FDG-avid lesions.
Conclusions: FDG-PET scanning is a simple, expensive, but powerful means to restage thyroid cancer patients who develop subsequent metastases, assigning them to groups that are either at low (FDG negative) or high (FDG positive) risk of cancer-associated mortality. We propose that the aggressiveness of therapy for metastases should match the FDG-PET status.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2005-1534</identifier><identifier>PMID: 16303836</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Age ; Age Factors ; Avidity ; Biological and medical sciences ; Carcinoma, Papillary, Follicular - blood ; Carcinoma, Papillary, Follicular - diagnostic imaging ; Carcinoma, Papillary, Follicular - metabolism ; Carcinoma, Papillary, Follicular - pathology ; Deoxyglucose ; Endocrinopathies ; Female ; Fluorodeoxyglucose F18 - pharmacokinetics ; Fundamental and applied biological sciences. Psychology ; Glucose ; Glycolysis ; Histology ; Humans ; Iodine Radioisotopes ; Lesions ; Male ; Malignant tumors ; Medical prognosis ; Medical sciences ; Metastases ; Metastasis ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Positron emission tomography ; Positron-Emission Tomography - methods ; Predictive Value of Tests ; Prognosis ; Radiopharmaceuticals - pharmacokinetics ; Scanning ; Sex Factors ; Survival ; Survival Analysis ; Thyroglobulin ; Thyroglobulin - blood ; Thyroid cancer ; Thyroid carcinoma ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - diagnostic imaging ; Thyroid Neoplasms - metabolism ; Thyroid Neoplasms - pathology ; Thyroid. Thyroid axis (diseases) ; Thyrotropin - blood ; Tomography ; Vertebrates: endocrinology</subject><ispartof>The journal of clinical endocrinology and metabolism, 2006-02, Vol.91 (2), p.498-505</ispartof><rights>Copyright © 2006 by The Endocrine Society 2006</rights><rights>Copyright © 2006 by The Endocrine Society</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5724-d154f9f207971d1a34e1714c6d226e5c5276ff5541a8b410ffc3fad17b4e8a3c3</citedby><cites>FETCH-LOGICAL-c5724-d154f9f207971d1a34e1714c6d226e5c5276ff5541a8b410ffc3fad17b4e8a3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17489974$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16303836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robbins, Richard J.</creatorcontrib><creatorcontrib>Wan, Qiang</creatorcontrib><creatorcontrib>Grewal, Ravinder K.</creatorcontrib><creatorcontrib>Reibke, Roland</creatorcontrib><creatorcontrib>Gonen, Mithat</creatorcontrib><creatorcontrib>Strauss, H. William</creatorcontrib><creatorcontrib>Tuttle, R. Michael</creatorcontrib><creatorcontrib>Drucker, William</creatorcontrib><creatorcontrib>Larson, Steven M.</creatorcontrib><title>Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid carcinoma is highly variable. We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[18F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis.
Design/Patients: The initial FDG-positron emission tomography (PET) scans from 400 thyroid cancer patients were retrospectively reviewed and compared with overall survival (median follow-up, 7.9 yr). We examined the prognostic value of clinical information such as gender, age, serum thyroglobulin, American Joint Committee on Cancer (AJCC) stage, histology, radioiodine avidity, FDG-PET positivity, number of FDG-avid lesions, and the glycolytic rate of the most active lesion.
Results: Age, initial stage, histology, thyroglobulin, radioiodine uptake, and PET outcomes all correlated with survival by univariate analysis. However, only age and PET results continued to be strong predictors of survival under multivariate analysis. The initial American Joint Committee on Cancer stage was not a significant predictor of survival by multivariate analysis. There were significant inverse relationships between survival and both the glycolytic rate of the most active lesion and the number of FDG-avid lesions.
Conclusions: FDG-PET scanning is a simple, expensive, but powerful means to restage thyroid cancer patients who develop subsequent metastases, assigning them to groups that are either at low (FDG negative) or high (FDG positive) risk of cancer-associated mortality. We propose that the aggressiveness of therapy for metastases should match the FDG-PET status.</description><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Avidity</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Papillary, Follicular - blood</subject><subject>Carcinoma, Papillary, Follicular - diagnostic imaging</subject><subject>Carcinoma, Papillary, Follicular - metabolism</subject><subject>Carcinoma, Papillary, Follicular - pathology</subject><subject>Deoxyglucose</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glucose</subject><subject>Glycolysis</subject><subject>Histology</subject><subject>Humans</subject><subject>Iodine Radioisotopes</subject><subject>Lesions</subject><subject>Male</subject><subject>Malignant tumors</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Metastasis</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Scanning</subject><subject>Sex Factors</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Thyroglobulin</subject><subject>Thyroglobulin - blood</subject><subject>Thyroid cancer</subject><subject>Thyroid carcinoma</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - diagnostic imaging</subject><subject>Thyroid Neoplasms - metabolism</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Thyrotropin - blood</subject><subject>Tomography</subject><subject>Vertebrates: endocrinology</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd2LEzEUxQdR3Lr65rMMiPpi1tx8zjxq3a7CiotWEERCmsm0qTPJmMyw9tl_3JQWCqKBJPfhd0_OzSmKx4AvgAB-tTUXBGOOgFN2p5hBzTiSUMu7xQxjAqiW5OtZ8SClLcbAGKf3izMQFNOKilnx-5PVHVq63pY3Max9SC6VbYjlBzvqNOrRmXK52cXgmnKuo3E-9Lp8o5NtyuBLgr5Btfi-6KYQAyLorQ2_dqhBV91kQrLoJuuNMYOXvUvJ5WIZ-rCOetjsys9Ge-_8-mFxr9Vdso-O93nxZXG5nL9D1x-v3s9fXyPDJWGoAc7auiVY1hIa0JRZkMCMaAgRlhtOpGhbzhnoasUAt62hrW5ArpitNDX0vHh-0B1i-DnZNKpsytiu096GKSkhBSWEiww-_Qvchin67E1REIwBUMEz9fJAmRhSirZVQ3S9jjsFWO2jUVuj9tGofTQZf3IUnVa9bU7wMYsMPDsCOhndtVF749KJk6yqa7kXYgfuNnSjjelHN93aqDY5yHGjcF5MyArllwXOB0Z5k33bi0NbmIb_OUVHp_RAWt8EE523Q7QpnT7hn_P9AQTYwlA</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>Robbins, Richard J.</creator><creator>Wan, Qiang</creator><creator>Grewal, Ravinder K.</creator><creator>Reibke, Roland</creator><creator>Gonen, Mithat</creator><creator>Strauss, H. William</creator><creator>Tuttle, R. Michael</creator><creator>Drucker, William</creator><creator>Larson, Steven M.</creator><general>Endocrine Society</general><general>Oxford University Press</general><general>Copyright by The Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>200602</creationdate><title>Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning</title><author>Robbins, Richard J. ; Wan, Qiang ; Grewal, Ravinder K. ; Reibke, Roland ; Gonen, Mithat ; Strauss, H. William ; Tuttle, R. Michael ; Drucker, William ; Larson, Steven M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5724-d154f9f207971d1a34e1714c6d226e5c5276ff5541a8b410ffc3fad17b4e8a3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Avidity</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Papillary, Follicular - blood</topic><topic>Carcinoma, Papillary, Follicular - diagnostic imaging</topic><topic>Carcinoma, Papillary, Follicular - metabolism</topic><topic>Carcinoma, Papillary, Follicular - pathology</topic><topic>Deoxyglucose</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glucose</topic><topic>Glycolysis</topic><topic>Histology</topic><topic>Humans</topic><topic>Iodine Radioisotopes</topic><topic>Lesions</topic><topic>Male</topic><topic>Malignant tumors</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Metastasis</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Scanning</topic><topic>Sex Factors</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Thyroglobulin</topic><topic>Thyroglobulin - blood</topic><topic>Thyroid cancer</topic><topic>Thyroid carcinoma</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - diagnostic imaging</topic><topic>Thyroid Neoplasms - metabolism</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Thyrotropin - blood</topic><topic>Tomography</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robbins, Richard J.</creatorcontrib><creatorcontrib>Wan, Qiang</creatorcontrib><creatorcontrib>Grewal, Ravinder K.</creatorcontrib><creatorcontrib>Reibke, Roland</creatorcontrib><creatorcontrib>Gonen, Mithat</creatorcontrib><creatorcontrib>Strauss, H. William</creatorcontrib><creatorcontrib>Tuttle, R. Michael</creatorcontrib><creatorcontrib>Drucker, William</creatorcontrib><creatorcontrib>Larson, Steven M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robbins, Richard J.</au><au>Wan, Qiang</au><au>Grewal, Ravinder K.</au><au>Reibke, Roland</au><au>Gonen, Mithat</au><au>Strauss, H. William</au><au>Tuttle, R. Michael</au><au>Drucker, William</au><au>Larson, Steven M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2006-02</date><risdate>2006</risdate><volume>91</volume><issue>2</issue><spage>498</spage><epage>505</epage><pages>498-505</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid carcinoma is highly variable. We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[18F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis.
Design/Patients: The initial FDG-positron emission tomography (PET) scans from 400 thyroid cancer patients were retrospectively reviewed and compared with overall survival (median follow-up, 7.9 yr). We examined the prognostic value of clinical information such as gender, age, serum thyroglobulin, American Joint Committee on Cancer (AJCC) stage, histology, radioiodine avidity, FDG-PET positivity, number of FDG-avid lesions, and the glycolytic rate of the most active lesion.
Results: Age, initial stage, histology, thyroglobulin, radioiodine uptake, and PET outcomes all correlated with survival by univariate analysis. However, only age and PET results continued to be strong predictors of survival under multivariate analysis. The initial American Joint Committee on Cancer stage was not a significant predictor of survival by multivariate analysis. There were significant inverse relationships between survival and both the glycolytic rate of the most active lesion and the number of FDG-avid lesions.
Conclusions: FDG-PET scanning is a simple, expensive, but powerful means to restage thyroid cancer patients who develop subsequent metastases, assigning them to groups that are either at low (FDG negative) or high (FDG positive) risk of cancer-associated mortality. We propose that the aggressiveness of therapy for metastases should match the FDG-PET status.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>16303836</pmid><doi>10.1210/jc.2005-1534</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2006-02, Vol.91 (2), p.498-505 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67632256 |
| source | Oxford University Press Journals; MEDLINE; EZB Electronic Journals Library |
| subjects | Adult Age Age Factors Avidity Biological and medical sciences Carcinoma, Papillary, Follicular - blood Carcinoma, Papillary, Follicular - diagnostic imaging Carcinoma, Papillary, Follicular - metabolism Carcinoma, Papillary, Follicular - pathology Deoxyglucose Endocrinopathies Female Fluorodeoxyglucose F18 - pharmacokinetics Fundamental and applied biological sciences. Psychology Glucose Glycolysis Histology Humans Iodine Radioisotopes Lesions Male Malignant tumors Medical prognosis Medical sciences Metastases Metastasis Middle Aged Multivariate Analysis Neoplasm Metastasis Positron emission tomography Positron-Emission Tomography - methods Predictive Value of Tests Prognosis Radiopharmaceuticals - pharmacokinetics Scanning Sex Factors Survival Survival Analysis Thyroglobulin Thyroglobulin - blood Thyroid cancer Thyroid carcinoma Thyroid Neoplasms - blood Thyroid Neoplasms - diagnostic imaging Thyroid Neoplasms - metabolism Thyroid Neoplasms - pathology Thyroid. Thyroid axis (diseases) Thyrotropin - blood Tomography Vertebrates: endocrinology |
| title | Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T17%3A31%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-Time%20Prognosis%20for%20Metastatic%20Thyroid%20Carcinoma%20Based%20on%202-%5B18F%5DFluoro-2-Deoxy-d-Glucose-Positron%20Emission%20Tomography%20Scanning&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Robbins,%20Richard%20J.&rft.date=2006-02&rft.volume=91&rft.issue=2&rft.spage=498&rft.epage=505&rft.pages=498-505&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.2005-1534&rft_dat=%3Cproquest_cross%3E67632256%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3164411365&rft_id=info:pmid/16303836&rft_oup_id=10.1210/jc.2005-1534&rfr_iscdi=true |